Toll Free: 1-888-928-9744

Global Antisense and RNAi Therapeutics Market Professional Survey Report 2016

Published: May 5, 2016 | Pages: 110 | Publisher: QYResearch | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

This report
Mainly covers the following product types
The segment applications including
Segment regions including (the separated region report can also be offered)
    USA
    China
    Europe
    South America
    Japan
    Africa
The players list (Partly, Players you are interested in can also be added)
    Alnylam Pharmaceuticals
    Isis Pharmaceuticals
    Sanofi
    Glaxosmithkline
    Pfizer
    Allergan
    Antisense Therapeutics
    Ascletis
    AstraZeneca
    Novartis
    Atlantic Pharmaceuticals
    Benitec Biopharma
    Biogen Idec
    Takeda Pharmaceutical
    Bristol-Myers Squibb
    Teva Pharmaceutical
    Dainippon Sumitomo Pharma
    Dicerna Pharmaceuticals
    Enzon Pharmaceuticals
    F. Hoffmann-La Roche
    Gradalis
    ICo Therapeutics
    Kyowa Hakko Kirin
    Marina Biotech
    Acuitas Therapeutics
    OncoGenex Pharmaceuticals
    OPKO Health
    Quark Pharmaceuticals
    Regulus Therapeutics
    Silence Therapeutics
    Spectrum Pharmaceuticals
    Sylentis
    The Medicines Company
    TransDerm
With no less than 15 top producers.

Data including (both global and regions): Market Size (both volume - Unit and value - million USD), Market Share, Production data, Consumption data, Trade data, Price - USD/Unit, Cost, Gross margin etc.

More detailed information, please refer to the attachment file and table of contents. If you have other requirements, please contact us, we can also offer!


 Table of Contents
1 Industry Overview of Antisense and RNAi Therapeutics 1.1 Definition and Specifications of Antisense and RNAi Therapeutics 1.1.1 Definition of Antisense and RNAi Therapeutics 1.1.2 Specifications of Antisense and RNAi Therapeutics 1.2 Classification of Antisense and RNAi Therapeutics 1.3 Applications of Antisense and RNAi Therapeutics 1.4 Industry Chain Structure of Antisense and RNAi Therapeutics 1.5 Industry Overview and Major Regions Status of Antisense and RNAi Therapeutics 1.5.1 Industry Overview of Antisense and RNAi Therapeutics 1.5.2 Global Major Regions Status of Antisense and RNAi Therapeutics 1.6 Industry Policy Analysis of Antisense and RNAi Therapeutics 1.7 Industry News Analysis of Antisense and RNAi Therapeutics 2 Manufacturing Cost Structure Analysis of Antisense and RNAi Therapeutics 2.1 Raw Material Suppliers and Price Analysis of Antisense and RNAi Therapeutics 2.2 Equipment Suppliers and Price Analysis of Antisense and RNAi Therapeutics 2.3 Labor Cost Analysis of Antisense and RNAi Therapeutics 2.4 Other Costs Analysis of Antisense and RNAi Therapeutics 2.5 Manufacturing Cost Structure Analysis of Antisense and RNAi Therapeutics 2.6 Manufacturing Process Analysis of Antisense and RNAi Therapeutics 3 Technical Data and Manufacturing Plants Analysis of Antisense and RNAi Therapeutics 3.1 Capacity and Commercial Production Date of Global Antisense and RNAi Therapeutics Major Manufacturers in 2015 3.2 Manufacturing Plants Distribution of Global Antisense and RNAi Therapeutics Major Manufacturers in 2015 3.3 R&D Status and Technology Source of Global Antisense and RNAi Therapeutics Major Manufacturers in 2015 3.4 Raw Materials Sources Analysis of Global Antisense and RNAi Therapeutics Major Manufacturers in 2015 4 Global Antisense and RNAi Therapeutics Overall Market Overview 4.1 2011-2016E Overall Market Analysis 4.2.1 2011-2015 Global Antisense and RNAi Therapeutics Capacity and Growth Rate Analysis 4.2.2 2015 Antisense and RNAi Therapeutics Capacity Analysis (Company Segment) 4.3 Sales Analysis 4.3.1 2011-2015 Global Antisense and RNAi Therapeutics Sales and Growth Rate Analysis 4.3.2 2015 Antisense and RNAi Therapeutics Sales Analysis (Company Segment) 4.4 Sales Price Analysis 4.4.1 2011-2015 Global Antisense and RNAi Therapeutics Sales Price 4.4.2 2015 Antisense and RNAi Therapeutics Sales Price Analysis (Company Segment) 4.5 Gross Margin Analysis 4.5.1 2011-2015 Global Antisense and RNAi Therapeutics Gross Margin 4.5.2 2015 Antisense and RNAi Therapeutics Gross Margin Analysis (Company Segment) 5 Antisense and RNAi Therapeutics Regional Market Analysis 5.1 USA Antisense and RNAi Therapeutics Market Analysis 5.1.1 USA Antisense and RNAi Therapeutics Market Overview 5.1.2 USA 2011-2016E Antisense and RNAi Therapeutics Local Supply, Import, Export, Local Consumption Analysis 5.1.3 USA 2011-2016E Antisense and RNAi Therapeutics Sales Price Analysis 5.1.4 USA 2015 Antisense and RNAi Therapeutics Market Share Analysis 5.2 China Antisense and RNAi Therapeutics Market Analysis 5.2.1 China Antisense and RNAi Therapeutics Market Overview 5.2.2 China 2011-2016E Antisense and RNAi Therapeutics Local Supply, Import, Export, Local Consumption Analysis 5.2.3 China 2011-2016E Antisense and RNAi Therapeutics Sales Price Analysis 5.2.4 China 2015 Antisense and RNAi Therapeutics Market Share Analysis 5.3 Europe Antisense and RNAi Therapeutics Market Analysis 5.3.1 Europe Antisense and RNAi Therapeutics Market Overview 5.3.2 Europe 2011-2016E Antisense and RNAi Therapeutics Local Supply, Import, Export, Local Consumption Analysis 5.3.3 Europe 2011-2016E Antisense and RNAi Therapeutics Sales Price Analysis 5.3.4 Europe 2015 Antisense and RNAi Therapeutics Market Share Analysis 5.4 South America Antisense and RNAi Therapeutics Market Analysis 5.4.1 South America Antisense and RNAi Therapeutics Market Overview 5.4.2 South America 2011-2016E Antisense and RNAi Therapeutics Local Supply, Import, Export, Local Consumption Analysis 5.4.3 South America 2011-2016E Antisense and RNAi Therapeutics Sales Price Analysis 5.4.4 South America 2015 Antisense and RNAi Therapeutics Market Share Analysis 5.5 Japan Antisense and RNAi Therapeutics Market Analysis 5.5.1 Japan Antisense and RNAi Therapeutics Market Overview 5.5.2 Japan 2011-2016E Antisense and RNAi Therapeutics Local Supply, Import, Export, Local Consumption Analysis 5.5.3 Japan 2011-2016E Antisense and RNAi Therapeutics Sales Price Analysis 5.5.4 Japan 2015 Antisense and RNAi Therapeutics Market Share Analysis 5.6 Africa Antisense and RNAi Therapeutics Market Analysis 5.6.1 Africa Antisense and RNAi Therapeutics Market Overview 5.6.2 Africa 2011-2016E Antisense and RNAi Therapeutics Local Supply, Import, Export, Local Consumption Analysis 5.6.3 Africa 2011-2016E Antisense and RNAi Therapeutics Sales Price Analysis 5.6.4 Africa 2015 Antisense and RNAi Therapeutics Market Share Analysis 6 Global 2011-2016E Antisense and RNAi Therapeutics Segment Market Analysis (by Type) 6.1 Global 2011-2016E Antisense and RNAi Therapeutics Sales by Type 6.2 Different Types Antisense and RNAi Therapeutics Product Interview Price Analysis 6.3 Different Types Antisense and RNAi Therapeutics Product Driving Factors Analysis 7 Global 2011-2016E Antisense and RNAi Therapeutics Segment Market Analysis (by Application) 7.1 Global 2011-2016E Consumption by Application 7.2 Different Application Product Interview Price Analysis 7.3 Different Application Product Driving Factors Analysis 8 Major Manufacturers Analysis of Antisense and RNAi Therapeutics 8.1 Alnylam Pharmaceuticals 8.1.1 Company Profile 8.1.2 Product Picture and Specifications 8.1.3 Alnylam Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.1.4 Alnylam Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.2 Isis Pharmaceuticals 8.2.1 Company Profile 8.2.2 Product Picture and Specifications 8.2.3 Isis Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.2.4 Isis Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.3 Sanofi 8.3.1 Company Profile 8.3.2 Product Picture and Specifications 8.3.3 Sanofi 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.3.4 Sanofi 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.4 Glaxosmithkline 8.4.1 Company Profile 8.4.2 Product Picture and Specifications 8.4.3 Glaxosmithkline 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.4.4 Glaxosmithkline 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.5 Pfizer 8.5.1 Company Profile 8.5.2 Product Picture and Specifications 8.5.3 Pfizer 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.5.4 Pfizer 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.6 Allergan 8.6.1 Company Profile 8.6.2 Product Picture and Specifications 8.6.3 Allergan 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.6.4 Allergan 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.7 Antisense Therapeutics 8.7.1 Company Profile 8.7.2 Product Picture and Specifications 8.7.3 Antisense Therapeutics 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.7.4 Antisense Therapeutics 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.8 Ascletis 8.8.1 Company Profile 8.8.2 Product Picture and Specifications 8.8.3 Ascletis 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.8.4 Ascletis 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.9 AstraZeneca 8.9.1 Company Profile 8.9.2 Product Picture and Specifications 8.9.3 AstraZeneca 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.9.4 AstraZeneca 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.10 Novartis 8.10.1 Company Profile 8.10.2 Product Picture and Specifications 8.10.3 Novartis 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.10.4 Novartis 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.11 Atlantic Pharmaceuticals 8.11.1 Company Profile 8.11.2 Product Picture and Specifications 8.11.3 Atlantic Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.11.4 Atlantic Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.12 Benitec Biopharma 8.12.1 Company Profile 8.12.2 Product Picture and Specifications 8.12.3 Benitec Biopharma 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.12.4 Benitec Biopharma 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.13 Biogen Idec 8.13.1 Company Profile 8.13.2 Product Picture and Specifications 8.13.3 Biogen Idec 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.13.4 Biogen Idec 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.14 Takeda Pharmaceutical 8.14.1 Company Profile 8.14.2 Product Picture and Specifications 8.14.3 Takeda Pharmaceutical 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.14.4 Takeda Pharmaceutical 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.15 Bristol-Myers Squibb 8.15.1 Company Profile 8.15.2 Product Picture and Specifications 8.15.3 Bristol-Myers Squibb 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.15.4 Bristol-Myers Squibb 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.16 Teva Pharmaceutical 8.16.1 Company Profile 8.16.2 Product Picture and Specifications 8.16.3 Teva Pharmaceutical 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.16.4 Teva Pharmaceutical 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.17 Dainippon Sumitomo Pharma 8.17.1 Company Profile 8.17.2 Product Picture and Specifications 8.17.3 Dainippon Sumitomo Pharma 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.17.4 Dainippon Sumitomo Pharma 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.18 Dicerna Pharmaceuticals 8.18.1 Company Profile 8.18.2 Product Picture and Specifications 8.18.3 Dicerna Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.18.4 Dicerna Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.19 Enzon Pharmaceuticals 8.19.1 Company Profile 8.19.2 Product Picture and Specifications 8.19.3 Enzon Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.19.4 Enzon Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.20 F. Hoffmann-La Roche 8.20.1 Company Profile 8.20.2 Product Picture and Specifications 8.20.3 F. Hoffmann-La Roche 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.20.4 F. Hoffmann-La Roche 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.21 Gradalis 8.21.1 Company Profile 8.21.2 Product Picture and Specifications 8.21.3 Gradalis 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.21.4 Gradalis 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.22 ICo Therapeutics 8.22.1 Company Profile 8.22.2 Product Picture and Specifications 8.22.3 ICo Therapeutics 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.22.4 ICo Therapeutics 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.23 Kyowa Hakko Kirin 8.23.1 Company Profile 8.23.2 Product Picture and Specifications 8.23.3 Kyowa Hakko Kirin 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.23.4 Kyowa Hakko Kirin 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.24 Marina Biotech 8.24.1 Company Profile 8.24.2 Product Picture and Specifications 8.24.3 Marina Biotech 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.24.4 Marina Biotech 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.25 Acuitas Therapeutics 8.25.1 Company Profile 8.25.2 Product Picture and Specifications 8.25.3 Acuitas Therapeutics 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.25.4 Acuitas Therapeutics 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.26 OncoGenex Pharmaceuticals 8.26.1 Company Profile 8.26.2 Product Picture and Specifications 8.26.3 OncoGenex Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.26.4 OncoGenex Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.27 OPKO Health 8.27.1 Company Profile 8.27.2 Product Picture and Specifications 8.27.3 OPKO Health 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.27.4 OPKO Health 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.28 Quark Pharmaceuticals 8.28.1 Company Profile 8.28.2 Product Picture and Specifications 8.28.3 Quark Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.28.4 Quark Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.29 Regulus Therapeutics 8.29.1 Company Profile 8.29.2 Product Picture and Specifications 8.29.3 Regulus Therapeutics 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.29.4 Regulus Therapeutics 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.30 Silence Therapeutics 8.30.1 Company Profile 8.30.2 Product Picture and Specifications 8.30.3 Silence Therapeutics 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.30.4 Silence Therapeutics 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.31 Spectrum Pharmaceuticals 8.31.1 Company Profile 8.31.2 Product Picture and Specifications 8.31.3 Spectrum Pharmaceuticals 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.31.4 Spectrum Pharmaceuticals 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.32 Sylentis 8.32.1 Company Profile 8.32.2 Product Picture and Specifications 8.32.3 Sylentis 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.32.4 Sylentis 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.33 The Medicines Company 8.33.1 Company Profile 8.33.2 Product Picture and Specifications 8.33.3 The Medicines Company 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.33.4 The Medicines Company 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 8.34 TransDerm 8.34.1 Company Profile 8.34.2 Product Picture and Specifications 8.34.3 TransDerm 2015 Antisense and RNAi Therapeutics Sales, Ex-factory Price, Revenue, Gross Margin Analysis 8.34.4 TransDerm 2015 Antisense and RNAi Therapeutics Business Region Distribution Analysis 9 Development Trend of Analysis of Market 9.1 Global Market Trend Analysis 9.1.1 Global 2016-2021 Market Size (Volume and Value) Forecast 9.1.2 Global 2016-2021 Sales Price Forecast 9.1.3 Global 2016-2021 Gross Margin Forecast 9.2 Regional Market Trend 9.2.1 USA 2016-2021 Antisense and RNAi Therapeutics Consumption Forecast 9.2.2 China 2016-2021 Antisense and RNAi Therapeutics Consumption Forecast 9.2.3 Europe 2016-2021 Antisense and RNAi Therapeutics Consumption Forecast 9.2.4 South America 2016-2021 Antisense and RNAi Therapeutics Consumption Forecast 9.2.5 Japan 2016-2021 Antisense and RNAi Therapeutics Consumption Forecast 9.2.6 Africa 2016-2021 Antisense and RNAi Therapeutics Consumption Forecast 9.3 Market Trend (Product type) 9.4 Market Trend (Application) 10 Antisense and RNAi Therapeutics Marketing Model Analysis 10.1 Antisense and RNAi Therapeutics Regional Marketing Model Analysis 10.2 Antisense and RNAi Therapeutics International Trade Model Analysis 10.3 Traders or Distributors with Contact Information of Antisense and RNAi Therapeutics by Regions 10.4 Antisense and RNAi Therapeutics Supply Chain Analysis 11 Consumers Analysis of Antisense and RNAi Therapeutics 11.1 Consumer 1 Analysis 11.2 Consumer 2 Analysis 11.3 Consumer 3 Analysis 11.4 Consumer 4 Analysis 12 New Project Investment Feasibility Analysis of Antisense and RNAi Therapeutics 12.1 New Project SWOT Analysis of Antisense and RNAi Therapeutics 12.2 New Project Investment Feasibility Analysis of Antisense and RNAi Therapeutics 13 Conclusion of the Global Antisense and RNAi Therapeutics Market Professional Survey Report 2016

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant

Read More...

Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the i

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...

Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energ

Read More...

Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global dem

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify